Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD (Lenalidomide, Doxorubicin, Dexamethasone) in Relapsed/Refractory Multiple Myeloma
NCT00306813Phase 2Completed
- Start
- Sep 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in multiple myeloma (MM). Primary endpoints: Maximum Tolerated Dose and Objective Response Rate. Started Sep 2004; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00306813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306813.